{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:39:38Z","timestamp":1780342778869,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T00:00:00Z","timestamp":1452556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Assess the efficacy and safety of abobotulinumtoxinA (Dysport\u00ae) in adult patients with neurogenic detrusor overactivity (NDO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This Phase IIa, international, multicentre, double\u2010blind, randomised, placebo controlled, pilot study enrolled 47 patients with NDO and urinary incontinence resulting from spinal cord injury (SCI) or multiple sclerosis (MS). Patients were treated with 15 intra\u2010detrusor injections of Dysport 750\u2009U or the equivalent placebo (n\u2009=\u200916 and 7) or 30 injections of Dysport 750\u2009U or the equivalent placebo (n\u2009=\u200917 and 7). Primary endpoint was change from baseline in mean number of daily incontinence episode frequency (IEF) at day 84. Secondary endpoints included change from baseline in urodynamic parameters and quality of life (QOL). A safety assessment was also conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Adjusted mean changes from baseline in IEF were \u22123.2 (\u221276%) and \u22121.7 (\u221215%) for 15 injections Dysport and placebo groups, respectively, (<jats:italic>P<\/jats:italic>\u2009=\u20090.1103) and \u22123.2 (\u221288%) and \u22122.6 (\u221273%) for 30 injections Dysport and placebo groups, respectively, (<jats:italic>P<\/jats:italic>\u2009=\u20090.0686). Statistically significant improvements in maximum cystometric capacity, maximum detrusor pressure and volume at first contraction were reported in the Dysport groups compared with placebo (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Improvements in QOL were reported. Three muscle weakness episodes were reported as serious adverse events in two tetraplegic and one paraplegic patient, all in the 15 injections Dysport group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both 15 and 30 injections administration modes of Dysport decreased daily IEF and resulted in significant improvements in urodynamic parameters in NDO patients with MS or SCI. Reduction to 15 injection sites did not appear to be associated with any impact on efficacy. <jats:italic>Neurourol. Urodynam. 36:457\u2013462, 2017<\/jats:italic>. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.22954","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T14:31:17Z","timestamp":1452609077000},"page":"457-462","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of two administration modes of an intra\u2010detrusor injection of 750 units dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo\u2010controlled phase IIa study"],"prefix":"10.1002","volume":"36","author":[{"given":"Pierre","family":"Denys","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation H\u00f4pital Raymond\u2010Poincar\u00e9 AP\u2010HP Garches France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Del Popolo","sequence":"additional","affiliation":[{"name":"Department of Neurourology Careggi University Hospital Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Amarenco","sequence":"additional","affiliation":[{"name":"Department of Neurourology H\u00f4pital Tenon Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Karsenty","sequence":"additional","affiliation":[{"name":"Department of Urology H\u00f4pital de la Conception Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Berre","sequence":"additional","affiliation":[{"name":"Ipsen Innovation Les Ulis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Padrazzi","sequence":"additional","affiliation":[{"name":"Ipsen Innovation Les Ulis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Picaut","sequence":"additional","affiliation":[{"name":"Ipsen Innovation Les Ulis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On Behalf of the Dysport Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2401"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-008-1042-y"},{"key":"e_1_2_7_4_1","unstructured":"BlokB PannekJ Castra DiazD et al.EEAU guidelines on neuro\u2010urology 2015.http:\/\/uroweb.org\/wp\u2010content\/uploads\/EAU\u2010Guidelines\u2010Neuro\u2010Urology\u20102015\u2010v2.pdfaccessed December2015."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00492-6"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.11.009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.035"},{"key":"e_1_2_7_9_1","first-page":"498","article-title":"English botulinum toxin\u2010A in the treatment of neurogenic detrusor overactivity","volume":"22","author":"Del Popolo G","year":"2003","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08466.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.09.034"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2005.19.880"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.08.016"},{"key":"e_1_2_7_14_1","first-page":"547","article-title":"Botulinum toxin\u2010A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)\u2010A prospective randomized study to compare 30 vs.10 injection sites","volume":"24","author":"Karsenty G","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.028"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.02.009"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.016"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.009"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21003"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22954","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:27:42Z","timestamp":1696400862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,12]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1002\/nau.22954"],"URL":"https:\/\/doi.org\/10.1002\/nau.22954","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,12]]}}}